Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-12-17
1995-08-29
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530407, 530303, 530399, A61K 3808, C12N 1518, C07K 1400
Patent
active
054460247
ABSTRACT:
A process for purifying IGF-I from variants of IGF-I is provided. In this process a mixture containing IGF-I and its variants is loaded onto a reversed-phase liquid chromatography column and the IGF-I is eluted from the column with a buffer at a pH of about 6-8. The buffer contains an alcoholic or polar aprotic solvent at a concentration of about 20-30% (v/v). This process can be preceded by a hydrophobic-interaction chromatography step.
REFERENCES:
patent: 4565785 (1986-01-01), Gilbert et al.
patent: 4673641 (1987-06-01), George et al.
patent: 4710473 (1987-12-01), Morris
patent: 4738921 (1988-04-01), Belagaje et al.
patent: 4782139 (1988-11-01), Di Marchi et al.
patent: 4795706 (1989-01-01), Hsiung et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5231178 (1993-07-01), Holz et al.
Bayne et al., "Expression, purification and characterization of recombinant human insulin-like growth factor I in yeast", Gene, 66:235-244 (1988).
Builder et al., "Analytical and Process Chromatography in Pharmaceutical Protein Production", Chemical Engineering Progress, 84(8):42-46 (1988).
Buttner et al., "Anomalous reversed-phase high-performance liquid chromatographic behavior of synthetic peptides related to antigenic helper T cell sites", Journal of Chromatography, 625:191-198 (1992).
Canalis et al., "Isolation and Characterization of Insulin-Like Growth Factor I (Somatomedin-C) from Cultures of Fetal Rat Calvariae*", Endocrinology, 122(1):22-27 (1988).
Cohen et al., "Mobile-Phase and Temperature Effects in the Reversed Phase Chromatographic Separation of Proteins", Analytical Biochemistry, 140:223-235 (1984).
Coombs, James, Dictionary of Biotechnology, 2nd Ed.:96 (1992).
DiMarchi et al., "Utilization of Analytical Reversed-Phase HPLC in Biosynthetic Insulin Production", High Performance Liquid Chromatography in Biotechnology, 8:181-189 (1990).
DiMarchi et al., "Synthesis of Insulin-Like Growth Factor I Through Recombinant DNA Techniques and Selective Chemical Cleavage at Tryptophan", Synthetic Peptides: Approaches to Biological Problems, pp. 283-294 (1989).
Elliott et al., "Yeast-Derived Recombinant Human Insulin-Like Growth Factor I: Production, and Structural Characterization", Journal of Protein Chemistry, 9(1):95-104 (1990).
Fink et al., "Characterization of the Unfolding of Ribonuclease A in Aqueous Methanol Solvents", Biochemistry, 26:1665-1671 (1987).
Forsberg et al., "Comparison of two chemical cleavage methods for preparation of a truncated form of recombinant human insulin-like growth factor I from a secreted fusion protein", BioFactors, 2(2):105-112 (1989).
Francis et al., "Purification and partial sequence analysis of insulin-like growth factor-1 from bovine colostrum", Biochem J., 233:207-213 (1986).
Frenz et al., "Reversed Phase Chromatography in Analytical Biotechnology of Proteins", HPLC of Biological Macromolecules, (6):145-177 (1990).
Furlanetto et al., "Estimation of Somatomedin-C Levels in Normals and Patients with Pituitary Disease by Radioimmunoassay", Journal of Clinical Investigation, 60:648:657 (1977).
Gospodarowicz et al., "Isolation of Pituitary Fibroblast Growth Factor by Fast Protein Liquid Chromatography (FPLC): Partial Chemical and Biological Characterization", Joural of Cellular Physiology, 122:323-332 (1985).
Horner et al., "Further Comparisons of the [.sup.125 I]Somatomedin A and the [.sup.125 I]Somatomedin C Radioreceptor Assays of Somatomedin Peptide", Journal of Clinical Endocrinology and Metabolism, 48(6):959-963.
Hummel et al., "Gene synthesis, expression in Escherichia coli and purification of immunoreactive human insulin-like growth factors I and II", Eur. J. Biochem., 180:555-561 (1989).
Jabri et al., "Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients", Diabetes, 43:369-374 (1994).
Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans", J. Clin. Invest., 91:141-147 (1993).
King et al., "Production and characterization of recombinant insulin-like growth factor-I (IGFD-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu.sup.3, following their expression in Escherichia coli as fusion proteins", J. Molecular Endocrinology, 8:29-41 (1992).
Kolaczynski et al., "Insulin-like Growth Factor-1 Therapy in Diabetes: Physiologic Basis, Clinical Benefits, and Risks", Annals of Internal Medicine, 120(1):47-55 (1994).
Kuzuya et al., "Trial of Insulinlike Growth Factor I Therapy for Patients With Extreme Insulin Resistance Syndromes", Diabetes(42):696-705 (1993).
Lau et al., "Effects of High-Performance Liquid Chromatographic Solvents and Hydrophobic Matrices on the Secondary and Quaternary Structure of a Model Protein", Journal of Chromatography, 317:129-140 (1984).
Mahoney et al., "Separation of Large Denatured Peptides by Reverse Phase High Performance Liquid Chromatography", Journal of Biological Chemistry, 255(23):11199-11203 (1980).
McKinnon et al., "Expression, purification and characterization of secreted recombinant human insulin-like growth factor-I (IGF-I) and the potent variant des(1-3)IGF-I in Chinese hamster ovary cells", Journal of Molecular Endocrinology, 6:231-239 (1991).
Monger et al., "Reversed-phase chromatographic behaviour of .beta.-endorphin: evidence of conformational change", Journal of Chromatography, 595:125-135 (1992).
Morrell et al., "Somatomedin C/insulin-like growth factor I: simplified purification procedure and biological activities of the purified growth factor", J. Endocr., 110:151-158 (1986).
Oroszlan et al., "Conformational Effects in the Reversed-Phase Chromatographic Behavior of Recombinant Human Growth Hormone (rhGH) and n-Methionyl Recombinant Human Growth Hormone (Met-hGH)", Anal. Chem., 64:1623-1631 (1992).
Regnier, Fred E., "High-Performance Liquid Chromatography of Proteins", Methods in Enzymology, 91:137, 180-190 (1983).
Riggin et al., "A Reversed-Phase High-Performance Liquid Chromatographic Method for Characterization of Biosynthetic Human Growth Hormone", Analytical Biochemistry, 167:199-209 (1987).
Sadler et al., "Protein Conformation and Reversed-Phase High-Performance Liquid Chromatography", J of Chromatography, 317:93-101 (1984).
Saito et al., "Production and Isolation of Recombinant Somatomedin C", J. Biochem., 101:123-134 (1987).
Schalch et al., "Short-term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus", J. of Clinical Endo. and Metabolism, 77(6):15631568 (1993).
Schoenle et al., "Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance", Diabetologia, 34:675-679 (1991).
Schweitzer, Philip A., "Handbook of Separation Techniques for Chemical Engineers", 2nd Edi.(2):101-103 (1988).
Straczek et al., "Purification and Characterization of Three Molecular Forms of Somatomedins/Insulin-Like Growth Factors From Human Cohn Paste IV", Biotechnology of plasma proteins; Colloque INSERM, 175:115-122 (1989).
Usala et al., "Brief Report: Treatment of Insulin-Resistant Diabetic Ketoacidosis With Insulin-Like Growth Factor I In An Adolescent With Insulin-Dependent Diabetes", The New England Journal of Medicine Brief Report, 327(12):853-857 (1992).
Van den Brande et al., "Isolation and partial characterization of IGF-like peptides from Cohn fraction IV of human plasma", Acta Endocrinologica, 122:683-695 (1990).
Wadensten et al., "Purification of Human Recombinant Insulin-Like Growth Factors (IGF:s) Using Kromasil.RTM. Reverse Phase Columns", KG--KabiGen, EN-Eka Nobel Industries Sweden, pp. 1-15.
Watson et al., "Multiple peak formation from reversed-phase liquid chromatography of recombinant human platelet-derived growth factor", J. of Chromatography, 606:165-170 (1992).
Welinder et al., "Bioactivity of Insulin and Iodinated Insulin after Reversed-Phase HPLC", High Performance Liquid Chromatography in Biotechnology, 4:79-90 (1984).
Welinder et al., "Reversed-Phase High-Performance Liquid Chromatographic Separation of the Four Monoiodoin
Builder Stuart E.
Ogez John R.
Olson Charles V.
Reifsnyder David
Genentech Inc.
Hasak Janet E.
Schain Howard E.
Touzeau Lynn
LandOfFree
Purification of insulin-like growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purification of insulin-like growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purification of insulin-like growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1819508